Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.

Continue Reading